OncoTargets and Therapy (Dec 2017)
Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis
Abstract
Sheng Chen,1,* Ning Na,2,* Zhixiang Jian1 1Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 2Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China *These authors contributed equally to this work Background: The relationship between platelet counts and pancreatic cancer as a prognostic factor has been reported in many studies. We aimed to evaluate the prognostic value of platelet counts in predicting the prognosis of pancreatic cancer patients.Methods: We searched PubMed, Medline, EMBASE, and Google Scholar for eligible studies up to May 2017. Information about the characteristics of the study and relevant outcomes was extracted. A meta-analysis was performed to analyze the prognostic value of platelet counts using the hazard ratio (HR) and 95% confidence intervals (CIs).Results: A total of 1,756 patients in 13 retrospective studies were included. The pooled HR of 1.51 (95% CI: 1.20–1.90, P<0.001) showed that patients with elevated platelet counts were expected to have poor overall survival after treatment. Subgroup analysis showed that prognostic value of platelet levels was stronger in patients who received surgical resection (HR =1.60, 95% CI: 1.09–2.34, P=0.02), followed by patients who received palliative therapy (HR =1.46, 95% CI: 1.03–2.06, P=0.03).Conclusion: Platelet counts could be a useful prognostic marker for pancreatic cancer. Patients with high platelet counts are expected to have poor survival. Keywords: pancreatic adenocarcinoma, blood parameters, platelet, prognosis, evidence-based medicine
